General contact

Head Office
Novartis International AG
CH-4002 Basel

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)


Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel

+41 61 324 79 44


Global Oncology Media Relations
Denise Brashear
Novartis Oncology Global Public Relations

+1 862 778 7336

Novartis Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

This site is not intended for U.S. residents.


  • Product Information

    Jakavi (ruxolitinib)

    Jakavi® (ruxolitinib) is an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases. Jakavi is approved by the European Commission for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea and for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis1.


    Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar tissue. Since the abnormal marrow can no longer produce enough normal blood cells, the spleen often becomes enlarged when it takes responsibility for blood cell creation2. Patients may also suffer debilitating symptoms, including fatigue/weakness, shortness of breath, fever/night sweats, itchy skin, bone/joint pain, abdominal pain and/or weight loss, and have a poor quality of life and shortened survival2,3,4. Jakavi directly targets the underlying mechanism of disease, significantly reducing the size of the spleen in patients with myelofibrosis and relieving symptoms regardless of JAK mutational status, disease subtype, or any prior treatment, including hydroxyurea1.

    Polycythemia Vera (PV)

    PV is a rare and incurable blood cancer associated with an overproduction of blood cells in the bone marrow that can cause serious cardiovascular complications, such as blood clots, stroke and heart attack5. Approximately 25% of patients with PV develop resistance to or intolerance of hydroxyurea and are considered to have uncontrolled disease6. This is typically defined as hematocrit levels greater than 45%, elevated white blood cell count and/or platelet count, and may be accompanied by debilitating symptoms and/or an enlarged spleen6,7,8. Jakavi has shown to improve two key measures of disease control, including hematocrit control without use of phlebotomy and spleen size reduction, and improved PV-related symptoms in adult patients with PV who are resistant to or intolerant of hydroxyurea9.

    This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

    Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization outside the United States. Jakavi is marketed in the United States by Incyte Corporation as Jakafi® for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea and for the treatment of patients with intermediate or high-risk myelofibrosis. The safety and efficacy profile of Jakavi has not yet been established outside the approved indications.


    1. Jakavi® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; Mar 2015.
    2. Leukemia & Lymphoma Society. " Myelofibrosis Facts." Available at:

      .Accessed July 2015.
    3. Mesa RA, Schwagera S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): An Evidence-Based Brief Inventory to Measure Quality of Life and Symptomatic Response to Treatment in Myelofibrosis. Leuk Res. 2009; 33:1199-1203.
    4. Cervantes F, Dupriez B, Pereira A, et al. New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–2901.
    5. Leukemia & Lymphoma Society. Polycythemia Vera Facts. June 2012. Available at

      Accessed July 2015.
    6. Alvarez-Larran A, Pereira A, Cervantes F, et al. Assessment and Prognostic Value of The European Leukemianet Criteria for Clinicohematologic Response, Resistance, and Intolerance to Hydroxyurea in Polycythemia Vera. Blood. 2012;119(6):1363–1369.
    7. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-Negative Classical Myeloproliferative Neoplasms; Critical Concepts and Management Recommendations from European LeukemiaNET. J Clin Oncol. 2011;29(6):761–770.
    8. Emanuel R, Dueck A, Geyer H, et al. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients with MPNs. J Clin Oncol.2012;30(33):4098–4103.
    9. Vannucchi A, et al. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. The New England Journal of Medicine. 2015;372:426–35.